Do You Believe in the Upside Potential of Atricure (ATRC)?

Core Insights - Riverwater Partners' Small Cap Strategy underperformed the Russell 2000 in Q2 2025 due to a focus on defensive holdings and market preference for low-quality companies [1] - AtriCure, Inc. (NASDAQ:ATRC) is highlighted as a key stock, with a one-month return of 0.45% and a 52-week gain of 33.98% [2] - AtriCure, Inc. specializes in surgical devices for cardiac tissue ablation and pain management, addressing a significant healthcare issue with over 37 million people affected by atrial fibrillation globally [3] Company Overview - AtriCure, Inc. is a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management [3] - The company operates in the cardiac and minimally-invasive ablation markets, providing products used in both open-heart and minimally invasive surgical procedures [3] - As of September 08, 2025, AtriCure, Inc. had a market capitalization of $1.789 billion, with shares closing at $36.00 [2]